Daiichi Sankyo

News

Astellas scores first US blood cancer approval with Xospata

The FDA has approved Astellas’ Xospata for certain patients with acute myeloid leukaemia – the company’s first drug approved in blood cancer.

Market Access

FDA grants leukaemia drug ‘breakthrough’ status

A leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator.

Event coverage

ASCO 2018 - Monday 4th June: BMS tries different tack as Mer...

Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow of data from its Keytruda checkpoint inhibitor drug at the conference in Chi

News

AZ tried to buy Daiichi Sankyo last year - report

Trading in shares of Daiichi Sankyo was suspended yesterday.

News

Daiichi Sankyo anticoagulant gains EU label boost

Label gives guidance in use when restoring normal heart rhythm

News

3D Japan flag (with clipping path)see more country...

Nissan stays in UK - but will Japanese pharma?

Japanese R&D investment could follow EMA out of UK - experts.

Astellas scores first US blood cancer approval with Xospata

FDA grants leukaemia drug ‘breakthrough’ status

ASCO 2018 - Monday 4th June: BMS tries different tack as Mer...

AZ tried to buy Daiichi Sankyo last year - report

Daiichi Sankyo anticoagulant gains EU label boost

Nissan stays in UK - but will Japanese pharma?

Dexcom is first to join FDA/CMS health tech pilot

Discover a new era of healthcare panel engagement: Grounded ...

Daiichi Sankyo

Editor's Picks